Program
raludotatug deruxtecan
Also written as “R-DXd”, “Raludotatug Deruxtecan” and “DS-6000a”.
In Merck’s pipeline, Raludotatug deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-CDH6 IgG1 monoclonal antibody linked to a topoi
. Its studies are mostly in Ovarian Neoplasms · Lung Neoplasms · Fallopian Tube Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Renal Cell, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 77 open or running | phase 3since Jul 29, 2026 | Jun 21, 2021 | Mar 27, 2029phase 2 · NCT06843447 |
| Daiichi Sankyo | 44 open or running | phase 3since Nov 27, 2023 | Dec 16, 2020 | Dec 30, 2026phase 1 · NCT04707248 |
- Named in Merck’s own pipeline as
raludotatug deruxtecan (MK-5909)
, phase 3, as of Nov 2, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- Co-developmentMerck develops it with Daiichi Sankyo, worldwide except Japan, where Daiichi Sankyo keeps the rights.Announced Oct 19, 2023 · Source: Merck, Oct 19, 2023
History and studies of Daiichi Sankyo only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 16, 2020First study: phase 1 study in Carcinoma, Renal CellFirst studyNCT04707248 · 179 enrolled · United States, Japan
- Jul 21, 2022Named raludotatug deruxtecanINNProposed as its International Nonproprietary Name in WHO's List 127
- Oct 19, 2023Merck develops it with Daiichi SankyoCo-developmentWorldwide except Japan, where Daiichi Sankyo keeps the rights · announced · Merck
- Nov 27, 2023Phase 3 study in Ovarian NeoplasmsNCT06161025 · 860 planned · United States, Australia, Brazil and more
- Oct 25, 2024Phase 2 study in Advanced Solid TumorNCT06660654 · 335 enrolled · United States, Belgium, China and more
- Aug 3, 2026Phase 3 study in Fallopian Tube NeoplasmsNCT07791732 · 600 planned
Ahead
- Dec 30, 2026Primary completion: phase 1 study in Carcinoma, Renal CellNCT04707248
- Feb 29, 2028Primary completion: phase 3 study in Ovarian NeoplasmsNCT06161025
- Jul 1, 2029Primary completion: phase 3 study in Fallopian Tube NeoplasmsNCT07791732
- Dec 30, 2029Primary completion: phase 2 study in Advanced Solid TumorNCT06660654
TargetBeta
“Raludotatug deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-CDH6 IgG1 monoclonal antibody linked to a topoi”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody against the tumor-associated antigen (TAA) cadherin-6 (CDH6; CDH-6) ”NCIt, by rule
Other programs on CDH6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| TJ102rule | phrontline-biopharma | phase 2 | 1 |
| Anti-CDH6 Antibody-drug Conjugate SIM0505rule | nextcure-inc | phase 1 | 1 |
Studies
All 4 Daiichi Sankyo leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07791732Fallopian Tube Neoplasms | 3 | Not yet recruiting | Jul 1, 2029 | 600 |
| NCT06660654Advanced Solid Tumor · United States, Belgium, China and more | 2 | Active, not recruiting | Dec 30, 2029 | 335 |
| NCT06161025Ovarian Neoplasms · United States, Australia, Brazil and more | 3 | Recruiting | Feb 29, 2028 | 860 |
| NCT04707248Carcinoma, Renal Cell · United States, Japan | 1 | Active, not recruiting | Dec 30, 2026 | 179 |
How it is read
Names in the registry
- “R-DXd”, 5 entries
- “Raludotatug Deruxtecan”, 2 entries
- “DS-6000a”, 2 entries
- “R-DXD”, 1 entry
- “Raludotatug deruxtecan”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 4 studies
- Lung Neoplasms, 1 study
- Fallopian Tube Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Carcinoma, Renal Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.